Pfizer fight with Starboard heats up, hedge fund alleges executive pressure
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the U.S. drugmaker to investigate actions by its board, after two former executives backed out of its campaign against the company.
Pfizer's CEO gains support of ex-execs amid activist investor talks
"We have decided not to be involved in the efforts of Starboard Value regarding Pfizer. We are fully supportive of Pfizer Chairman & CEO Albert Bourla, senior management and the board, and we are confident that over time they will deliver shareholder value," the two wrote, in a statement issued on behalf of them by Guggenheim Securities.
Activist investor Starboard accuses Pfizer of strong-arming former execs into backing CEO Bourla ahead of strategy meeting
Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting with activist investor Starboard Value, Pfizer's former CEO and CFO publicly changed their tune after being threatened with litigation by Pfizer,
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...
As the battle over Pfizer’s future continues, former executives said they would no longer support activist investor Starboard ...
Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board ...
Two former Pfizer executives said they will not be involved with activist investor Starboard Value, which reportedly wants ...
(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback